Altamira Therapeutics Ltd

Altamira Therapeutics Ltd

CYTO - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$62.99K
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Altamira Therapeutics LtdAltamira Therapeutics Ltd0--241%-0.10.1
$1.18

Current Fair Value

293.6% upside

Undervalued by 293.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$62,987.00
Enterprise Value$-574,584.00
Earnings per Share$-14.81
Beta2.44
Outstanding Shares209,955

Return

Return on Equity-241.19%ROE
Return on Assets-183.01%
Return on Invested Capital-34.88%

Valuation & Multiples

P/E Ratio-0.02P/E Ratio
PEG0.06PEG
Price to Sales-0.15Price to Sales
Price to Book Ratio0.01Price to Book Ratio
Enterprise Value to Revenue-1.4
Enterprise Value to EBIT-0.19
Enterprise Value to Net Income0
Total Debt to Enterprise0.73
Debt to Equity0.05Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Altamira Therapeutics Ltd

17 employees
CEO: Thomas Meyer

Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal be...

Altamira Therapeutics Insider Information FAQ

In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.